🌿 Atomoxetine Norepinephrine Reuptake Simulator

Baseline Prefrontal Cortex Signaling

Untreated PFC clears norepinephrine and dopamine quickly, limiting attention signaling.

• 100%: Baseline NET activity (full reuptake capacity)
• ~2 min: Synaptic NE half-life (rapid clearance)
• NET-cleared: PFC dopamine source (sparse DAT here)
• Weak: Attention signal (untreated ADHD state)

Why the PFC clears NE fast

NET pumps recycle norepinephrine back into the presynaptic terminal quickly.

PFC dopamine is different

Prefrontal cortex has few dopamine transporters, so NET also clears dopamine here.

This dual role of NET in the PFC is the key to atomoxetine's mechanism.

Consequence for attention

Fast clearance means weak, short-lived catecholamine signaling and poor executive control.

Atomoxetine Reaches the Synapse

Atomoxetine is absorbed and travels to NET sites on PFC neurons.

• Non-stimulant: Drug class (selective NRI)
• NET: Target (norepinephrine transporter)
• ~1–2 h: Time to peak plasma (oral dosing)
• None: Abuse potential (not a controlled substance)

Selective transporter targeting

Atomoxetine binds NET with high affinity, sparing dopamine and serotonin transporters.

Non-stimulant mechanism

It does not release stored catecholamines, unlike stimulant ADHD medications.

Selectivity for NET over DAT is why it avoids the euphoric rush of stimulants.

Onset is gradual

Molecules progressively occupy transporter sites over the first days of dosing.

NET Blocked, Norepinephrine Accumulates

With NET occupied, norepinephrine lingers in the synapse instead of recycling.

• >70%: NET occupancy needed (for clinical effect)
• 2–3×: Synaptic NE rise (above baseline)
• Yes: Reuptake blocked (NE stays extracellular)
• Prolonged: Receptor exposure (stronger post-synaptic signal)

Occupancy drives effect

Higher NET occupancy correlates with greater extracellular norepinephrine buildup.

Prolonged receptor stimulation

Accumulated NE binds post-synaptic adrenergic receptors longer, strengthening signal transmission.

Sustained NE elevation is the direct driver of improved PFC circuit signaling.

Dose-dependent blockade

Higher doses occupy more transporter sites, raising synaptic norepinephrine further.

Dopamine Rises Selectively in the PFC

Because PFC dopamine is cleared via NET, blocking NET raises dopamine too.

• Moderate: PFC dopamine rise (via NET co-clearance)
• Unchanged: Striatal dopamine (DAT-dependent region)
• Indirect: Mechanism (not direct DAT block)
• PFC only: Region specificity (no striatal surge)

A regional quirk

Striatal regions rely on dense DAT, so NET blockade does not touch them.

Two transporters, two outcomes

PFC dopamine rises with NET blockade; striatal dopamine stays exactly the same.

This regional split explains why atomoxetine lacks stimulant-like abuse potential.

Slow, steady accumulation

The dopamine rise builds gradually over weeks of consistent dosing.

Improved Attention Without Abuse Risk

Dual NE and DA elevation in the PFC sharpens focus, with no reward surge.

• 4–8 wk: Onset to full effect (slower than stimulants)
• Improved: Executive function (sustained NE + DA)
• None: Striatal reward surge (no euphoria/high)
• Unscheduled: Scheduled substance status (no abuse potential)

Slow onset, durable effect

Full clinical benefit builds over several weeks rather than minutes.

Dual-neurotransmitter benefit

Combined NE and DA elevation strengthens PFC attention and executive circuits.

The PFC-restricted dopamine rise gives cognitive benefit without triggering reward pathways.

No reinforcing potential

Unaffected striatal dopamine means no rapid high and no dependence risk.